Skip to main content
PMC home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1963 Dec 14;89(24):1207–1211.

Blood Coagulation and Platelet Economy in Subjects with Primary Gout

J F Mustard, E A Murphy, M A Ogryzlo, H A Smythe
PMCID: PMC1922159  PMID: 14084698

Abstract

Previous studies have suggested that there is an increased incidence of degenerative vascular disease in patients with gout and an increased rate of turnover of blood platelets in patients and animals with atherosclerosis. A disturbed uric acid metabolism and “secondary” gout have long been known to occur with bone marrow diseases. A study of platelet economy and blood clotting factors in subjects with primary gout was therefore undertaken.

Twenty-two male subjects with gout but with no clinical evidence of vascular disease were studied. Half of these had a negative family history for vascular disease and half had less fortunate ancestors. The most striking differences were found when gouty patients with a negative family history for vascular disease were compared with similar control subjects. The mean platelet half-life was 2.85 days in the gouty subjects and 3.74 days in the controls. The mean platelet turnover (number/c.mm./day) was 58,750 in gouty subjects, 42,370 in controls. Platelet adhesiveness and plasma thromboplastic activity were correspondingly increased in the gouty subjects. Control subjects with a positive family history all showed relatively active clotting system and platelet turnover, similar to the values found in atherosclerotic subjects. The data indicated that there is increased platelet destruction and production in some patients with primary gout. The relation between this anomaly and the vascular disease, and disturbed urate metabolism in gouty subjects, remains to be investigated.

Full text

PDF
1207

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARCHIBALD R. M. Colorimetric measurement of uric acid. Clin Chem. 1957 Apr;3(2):102–105. [PubMed] [Google Scholar]
  2. ASK-UPMARK E., ADNER L. Coronary infarction and gout. Acta Med Scand. 1951;139(1):1–6. doi: 10.1111/j.0954-6820.1950.tb17139.x. [DOI] [PubMed] [Google Scholar]
  3. BELL J. C., RIEMENSNIDER D. K., MITCHELL R. S. Effect of certain aromatic amines on serum isoniazid concentrations in tuberculous patients. Am Rev Tuberc. 1957 Jul;76(1):152–158. doi: 10.1164/artpd.1957.76.1.152. [DOI] [PubMed] [Google Scholar]
  4. BENEDICT J. D., YU T. F., BIEN E. J., GUTMAN A. B., STETTEN D., Jr A further study of the utilization of dietary glycine nitrogen for uric acid synthesis in gout. J Clin Invest. 1953 Aug;32(8):775–777. doi: 10.1172/JCI102791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. BERTE S. J., LEIFHEIT H. C., DEWLETT H. J., TUCKER E. B. A critical analysis of the accuracy of a chemical and biologic method of determining serum free isoniazid. Am Rev Tuberc. 1959 Mar;79(3):344–350. doi: 10.1164/artpd.1959.79.3.344. [DOI] [PubMed] [Google Scholar]
  6. COHEN J. A., LEEKSMA C. H. Determination of the life span of human blood platelets using labelled diisopropylfluorophosphonate. J Clin Invest. 1956 Sep;35(9):964–969. doi: 10.1172/JCI103356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. CUTHBERTSON W. F., IRELAND D. M., WOLFF W. Detection and identification of some metabolites of isonicotinic acid hydrazide (isoniazid) in human urine. Biochem J. 1953 Nov;55(4):669–671. doi: 10.1042/bj0550669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. GANGADHARAM P. R., DEVADATTA S., FOX W., NAIR C. N., SELKON J. B. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS. Bull World Health Organ. 1961;25:793–806. [PMC free article] [PubMed] [Google Scholar]
  10. GUTMAN A. B. A view of gout as inborn error of metabolism. Am J Med. 1960 Oct;29:545–553. doi: 10.1016/0002-9343(60)90089-9. [DOI] [PubMed] [Google Scholar]
  11. GUTMAN A. B. Primary and secondary gout. Ann Intern Med. 1953 Nov;39(5):1062–1076. doi: 10.7326/0003-4819-39-5-1062. [DOI] [PubMed] [Google Scholar]
  12. HARRIS H. W., KNIGHT R. A., SELIN M. J. Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. Am Rev Tuberc. 1958 Dec;78(6):944–948. doi: 10.1164/artpd.1958.78.6.944. [DOI] [PubMed] [Google Scholar]
  13. HICKLING R. A. Leukaemia and related conditions and the blood-uric-acid. Lancet. 1958 Jan 25;1(7013):175–178. doi: 10.1016/s0140-6736(58)90664-0. [DOI] [PubMed] [Google Scholar]
  14. JENNE J. W., MACDONALD F. M., MENDOZA E. A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and paraminosalicylic acid in man. Am Rev Respir Dis. 1961 Sep;84:371–378. doi: 10.1164/arrd.1961.84.3.371. [DOI] [PubMed] [Google Scholar]
  15. JOHNSON W., CORTE G. Inhibition of isoniazid acetylation in vitro and vivo. Proc Soc Exp Biol Med. 1956 Jun;92(2):446–448. doi: 10.3181/00379727-92-22505. [DOI] [PubMed] [Google Scholar]
  16. KOHN P. M., PROZAN G. B. Hyperuricemia; relationship to hypercholesteremia and acute myocardial infarction. J Am Med Assoc. 1959 Aug 15;170(16):1909–1912. doi: 10.1001/jama.1959.03010160025007. [DOI] [PubMed] [Google Scholar]
  17. MITCHELL R. S., BELL J. C. Clinical implications of isoniazid blood levels in pulmonary tuberculosis. N Engl J Med. 1957 Nov 28;257(22):1066–1070. doi: 10.1056/NEJM195711282572202. [DOI] [PubMed] [Google Scholar]
  18. MURPHY E. A., MUSTARD J. F. Coagulation tests and platelet economy in atherosclerotic and control subjects. Circulation. 1962 Jan;25:114–125. doi: 10.1161/01.cir.25.1.114. [DOI] [PubMed] [Google Scholar]
  19. MURPHY E. A., MUSTARD J. F. Dicumarol therapy. Some effects on platelets and their relationship to clotting tests. Circ Res. 1960 Nov;8:1187–1199. doi: 10.1161/01.res.8.6.1187. [DOI] [PubMed] [Google Scholar]
  20. MUSTARD J. F., MURPHY E. A. Effect of different dietary fats on blood coagulation, platelet economy, and blood lipids. Br Med J. 1962 Jun 16;1(5293):1651–1655. doi: 10.1136/bmj.1.5293.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. PETERS J. H. Studies on the metabolism of isoniazid. 2. The influence of para-aminosalicylic acid on the metabolism of isoniazid by man. Am Rev Respir Dis. 1960 Aug;82:153–163. doi: 10.1164/arrd.1960.82.2.153. [DOI] [PubMed] [Google Scholar]
  22. PFAFFENBERG R. [On the significance of isoniazid metabolism as a hereditary metabolic characteristic of normal persons]. Klin Wochenschr. 1961 Feb 15;39:204–205. doi: 10.1007/BF01482955. [DOI] [PubMed] [Google Scholar]
  23. SHORT E. I. A comparative study of the metabolism and toxicity of isoniazid and isoniazone calcium pyruvate. Tubercle. 1962 Mar;43:22–32. doi: 10.1016/s0041-3879(62)80045-2. [DOI] [PubMed] [Google Scholar]
  24. SORENSEN L. B. The pathogenesis of gout. Arch Intern Med. 1962 Apr;109:379–390. doi: 10.1001/archinte.1962.03620160005002. [DOI] [PubMed] [Google Scholar]
  25. THANNHAUSER S. J. The pathogenesis of gout. Metabolism. 1956 Sep;5(5):582–593. [PubMed] [Google Scholar]
  26. WYNGAARDEN J. B. Intermediary purine metabolism and the metabolic defects of gout. Metabolism. 1957 May;6(3):244–268. [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES